Module

Safety and Tolerability of Recommended Regimens for First-Line Therapy

Source: Right From the Start: Optimizing First-Line Antiretroviral Therapy

Safety and Tolerability of Recommended Regimens for First-Line Therapy

Program Chair: William G. Powderly, MD

Faculty:
Paul E. Sax, MD

CME CREDIT INFORMATION

Release Date: 10/04/07

Expiration Date: 10/03/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

List the most common adverse events associated with each of the agents recommended by the DHHS and IAS-USA guidelines for use in first-line regimens
Summarize data from clinical trials that have highlighted differences in the incidence of adverse events associated with recommended first-line regimens
Discuss potential screening and patient selection strategies that may reduce the risk of development of certain adverse events in patients receiving first-line therapy

Topics covered include:

Introduction
Comparison of DHHS and IAS-USA Guidelines for Initial Therapy
First-Line Therapy Options: NRTIs—Zidovudine/Lamivudine
First-Line Therapy Options: NRTIs—Tenofovir/Emtricitabine
First-Line Therapy Options: NRTIs—Abacavir/Lamivudine
First-Line Therapy Options: NNRTIs—Efavirenz
First-Line Therapy Options: NNRTIs—Nevirapine
First-Line Therapy Options: Boosted PIs—Lopinavir/Ritonavir
First-Line Therapy Options: Boosted PIs—Atazanavir/Ritonavir
First-Line Therapy Options: Boosted PIs—Fosamprenavir/Ritonavir
First-Line Therapy Options: Boosted PIs—Saquinavir/Ritonavir
Summary and Future Directions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.